Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial Of Novel Bone Disease Therapy
Velcura Therapeutics, Inc. announced the successful completion of a first-in-man clinical trial for its lead compound, VEL-0230, which the company is investigating as a treatment for Rheumatoid Arthritis (RA) and other bone diseases. In extensive preclinical studies, VEL-0230 proved to be a powerful anti-inflammatory agent that also stimulates bone formation and inhibits bone loss.
Prestigious Janssen Award Received By Researchers Who Helped Millions With Arthritis
Two British researchers who pioneered treatments which have helped millions of people with rheumatoid arthritis and other autoimmune diseases have been awarded the prestigious 2008 Dr. Paul Janssen Award for Biomedical Research.
Breastfeeding And Arthritis
"Breast feeding your baby for at least a year can dramatically reduce the chance of contracting rheumatoid arthritis", the Daily Express reported. It went on to say that a study has found that women who breastfeed their babies for more than 13 months are half as likely to develop rheumatoid arthritis as women who don't.
Medarex Announces Initiation Of Phase 2 Clinical Trials For The Treatment Of Ulcerative Colitis And Rheumatoid Arthritis
Medarex, Inc. (Nasdaq: MEDX) announced that it has initiated the Phase 2 clinical development program of MDX-1100, a fully human monoclonal antibody that targets CXCL10 (also known as IP-10), in ulcerative colitis (UC) and rheumatoid arthritis (RA).
Rheumatoid Arthritis - MorphoSys Announces Completion Of First Dosing In Phase 1 Trial For MOR103 Program
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced the completion of a first dosing regimen in a phase 1 clinical study on healthy volunteers of the HuCAL-derived antibody MOR103 with no adverse events reported. Six healthy volunteers in the first dosing group have been enrolled and received MOR103 injections, three volunteers received placebo.
Rheumatoid Arthritis Patients Not To Have Access To Treatment If First One Is Unsuitable, England
A decision by NICE (National Institute for Clinical Excellence) means that rheumatoid arthritis (RA) patients will not have access to a second anti-TNF treatment if the first one is found to be unsuitable. The Arthritis and Musculoskeletal Alliance says this latest decision seems to have forgotten all about patient choice in England, while those in Scotland will be able to move from one treatment to another if the first one proved unsuitable.
NICE Preliminary Decision On Sequential Use Of Anti-TNFs, NICE 'Penny-Pinching' Restricts Patient Choice
A leading arthritis charity accused the government's health rationing watchdog of 'penny-pinching' in its decision to refuse thousands of people the chance to try an alternative life-changing anti-TNF drug if a first does not work for them. 'Anti-TNFs can slow down the progress of rheumatoid arthritis.
Rheumatoid Arthritis: Fully-automated Anti-CCP Assay Launched By Roche Diagnostics
Roche Diagnostics announced the launch of a fully-automated immunoassay for the determination of autoantibodies to cyclic citrullinated peptides (Anti-CCP). The assay has been CE approved for use on the Elecsys / cobas e electrochemiluminescence immunoassay systems.
Increased Risks For Infection And Dislocation Faced By Obese Patients Following Revision Hip Replacement Surgery
Along with age and injuries, obesity is a leading risk factor for osteoarthritis (OA), a painful and disabling joint disease. While excessive weight can aggravate the toll on almost any joint, obesity has been associated with a higher prevalence of hip OA and an increase in total hip arthroplasty (THA).
Medication For Juvenile Rheumatoid Arthritis Confirmed Effective By Study
Juvenile rheumatoid arthritis (JRA) is a chronic autoimmune disease that strikes children between the ages of newborn to 16 years. All children with JRA have joint pain, stiffness, and swelling and some also have fever and skin rashes. JRA can impede growth, damage joints, and lead to disability in adulthood.